Dapagliflozin and Empagliflozin in Heart Failure | IJGM
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, are a new type of oral glucose-lowering drugs that can control blood glucose by inhibiting SGLT2 in the kidney. The DAPA-HF trial and the EMPEROR-Reduced trial suggested that dapagliflozin and empagliflozin, respectively, could lower the incidences of cardiovascular adverse events in patients suffering from heart failure with reduced ejection fraction (HFrEF).
Conclusion: Despite its many limitations, this study suggested that different SGLT2 inhibitors might have differences regarding efficacy in HFrEF. We look forward to future studies to verify our conjectures.